Alex Villiger is the Chief Financial Officer of the Celonic Group responsible for Group finance and IT. He is a member of the Celonic Group Executive Committee.

Alex holds a Masters of Arts from the University of St. Gallen (HSG), Switzerland, with a focus on Finance & Controlling, and is a certified Swiss Chartered Public Accountant.

He brings a wealth of professional experience and business expertise to this role.

Most recently, Alex served as the Vice President of Finance at Anjarium Biosciences, a pioneering genetic bioservices company dedicated to developing and delivering scalable synthetic DNA for viral vector manufacturing, mRNA production, and gene therapy delivery applications. Prior to that, Alex held positions of increasing responsibility in several global Pharma, Biotech and CDMO companies, including Novartis, Celonic and Polpharma Biologics. At Novartis, Alex held senior financial and commercial roles, spanning from 2002 to 2020, including Head Finance of the impactful “Customer First” commercial program and Global Head of Finance Biopharmaceutical Process and Drug Development. Alex received the Novartis Group Finance Excellent award in 2015 for his crucial role in setting up the new Novartis Business Services (NBS) organization.